[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Benedetti-Panici P, Zullo MA, Plotti F, Manci N, Muzii L, Angioli R: Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy. Cancer; 2004 May 15;100(10):2110-7
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy.
  • BACKGROUND: The objective of the current study was to evaluate the incidence of long-term bladder dysfunction after type 3-4 radical hysterectomy in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy (NACT).
  • METHODS: A case-control study was conducted to evaluate the occurrence of long-term bladder dysfunction in 76 patients with International Federation of Gynecology and Obstetrics Stage IB-IIA (> 4 cm), Stage IIB, and Stage III cervical carcinoma who underwent type 3-4 radical hysterectomy after NACT.
  • CONCLUSIONS: The observed rate of bladder dysfunction was higher than the corresponding rate reported in the literature (76%).
  • Three main disturbances were found: detrusor overactivity (21%), mixed urinary incontinence (24%), and de novo stress incontinence (21%).
  • Detrusor overactivity was related to a prevalence of hypertonic bladder.
  • Among patients who underwent type 4 radical hysterectomy, the extent of caudal resection of rectovaginal ligaments and vaginal tissue was found to be more strongly associated with bladder dysfunction than was the extent of lateral parametrial resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hysterectomy. Urinary Bladder / physiopathology. Uterine Cervical Neoplasms / physiopathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Time Factors. Urinary Incontinence, Stress / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139052.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Raghavan D: Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer; 2003 Apr 15;97(8 Suppl):2050-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the chemotherapy of metastatic cancer of the urinary tract.
  • Cytotoxic chemotherapy has an evolving role in the management of metastatic cancer of the bladder and urinary tract.
  • Standard single agents (e.g., methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, and cisplatin) have produced objective response rates of 15-25% and combination chemotherapy has resulted in objective regression in 40-75% of cases.
  • Traditional cytotoxic regimens have been ineffective in the management of adenocarcinoma and squamous cell carcinoma of the bladder.
  • Nevertheless, stage migration may produce the semblance of improved survival, which may reflect reduced tumor burden (via reclassification) and case selection.
  • Because historically controlled comparisons may introduce errors from case selection bias, stage migration, differences in duration of follow-up, and the evolution of supportive care, it is essential to validate the role of new agents in well structured, randomized clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / secondary. Humans. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society
  • (PMID = 12673696.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


3. Watanabe Y, Itoh S, Mitsuhata N: [Urachal carcinoma treated with neoadjuvant intra-arterial chemotherapy: a case report]. Hinyokika Kiyo; 2004 Oct;50(10):713-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urachal carcinoma treated with neoadjuvant intra-arterial chemotherapy: a case report].
  • Ultrasonography and computed tomography demonstrated a tumor at the bladder dome.
  • Cold punch biopsy revealed well-differentiated adenocarcinoma and stage III A urachal carcinoma was diagnosed.
  • Neoadjuvant intra-arterial chemotherapy with cisplatin, adriamycin and angiotensin II was performed and 40% reduction of tumor size was noted 3 weeks after this therapy.
  • Augmentation ilealcystoplasty was subsequently performed to secure bladder capacity.
  • Adjuvant chemotherapy (UFT) was given for 1 year.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Agents / administration & dosage. Tegafur / administration & dosage. Urachus. Uracil / administration & dosage
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intra-Arterial. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575224.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


Advertisement
4. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Pathological examinations of the transurethral and transvaginal needle biopsy specimen suggested mucinous adenocarcinoma.
  • First, the patient received local chemoradiotherapy and systemic chemotherapy using a fluoropyrimidine drug TS-1 and cisplatin.
  • The tumor markers declined to within normal limits after this preoperative therapy.
  • Histopathological examination of the surgical specimen showed mutinous adenocarcinoma invading to the vesical triangle and the anterior vaginal wall.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Hamasaki T, Kondo Y, Ogata Y, Yoshida K, Kimura G, Shimizu H, Nishimura T: Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol; 2010 Feb;15(1):109-11
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.
  • Random bladder biopsies showed no malignancy, but a second TUR-P revealed urothelial carcinoma in the prostate and bladder neck.
  • Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed.
  • Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m(2), ifosfamide 1.2 g/m(2) and docetaxel 70 mg/m(2) (PIT) was considered.
  • After chemotherapy, CT showed complete response (CR) of all lymph nodes.
  • Local control in the bladder was considered to be good, so total prostatectomy and retroperitoneal lymph node dissection was selected instead of total cystoprostatectomy.
  • Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / secondary. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Prostatectomy. Prostatic Hyperplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 Nov;48(5):703-10 [8911513.001]
  • [Cites] Am J Clin Pathol. 1963 Aug;40:183-9 [14060023.001]
  • [Cites] J Urol. 1973 Mar;109(3):457-60 [4348139.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Hinyokika Kiyo. 2000 Jul;46(7):495-8 [10965459.001]
  • [Cites] Urology. 1984 Dec;24(6):544-9 [6506393.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Br J Urol. 1979 Dec;51(6):575-8 [534844.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):50-61 [17280908.001]
  • [Cites] Hinyokika Kiyo. 1970 Apr;16(4):157-61 [5463380.001]
  • (PMID = 20087614.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Hongoh S, Nomoto T, Kawakami M, Hanai K, Inatsuchi H, Terachi T: [Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report]. Hinyokika Kiyo; 2010 Feb;56(2):107-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report].
  • Cystoscopy revealed a papillary tumor at the urinary bladder dome.
  • Abdominal magnetic resonance imaging (MRI) and computed tomography(CT) demonstrated a tumor extending from the umbilicus to the bladder dome.
  • Transurethral resection of bladder tumor (TUR-Bt) was performed and histopathological findings revealed adenocarcinoma.
  • The tumor was diagnosed as stage IIIA urachal carcinoma, and en bloc segmental resection was performed.
  • After two courses of combination chemotherapy with methotrexate (MTX), 5-fluorouracil (5-FU), epirubicin (epiADM), and cisplatin (CDDP), the multiple lung metastases completely disappeared.
  • The patient has survived 23 months to date with no evidence of disease and is receiving adjuvant chemotherapy with tegafur uracil.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185997.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Holmäng S, Aldenborg F: Stage T1 adenocarcinoma of the urinary bladder--complete response after transurethral resection and intravesical bacillus Calmette-Guerin. Scand J Urol Nephrol; 2000 Apr;34(2):141-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage T1 adenocarcinoma of the urinary bladder--complete response after transurethral resection and intravesical bacillus Calmette-Guerin.
  • OBJECTIVE: To report the results of treatment of adenocarcinoma of the urinary bladder with transurethral resection and intravesical bacillus Calmette-Guerin (BCG).
  • METHODS: Out of 183 patients in our department treated with BCG between 1992 and 1996, three patients had adenocarcinoma, stage T1.
  • RESULTS: All three patients had normal cystoscopy and negative cytology 53-82 months after the start of treatment.
  • CONCLUSIONS: BCG appears to be effective not only in the treatment of transitional cell carcinoma, but also in adenocarcinoma of the bladder.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10903079.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWEDEN
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


8. Sekita N, Fujimura M, Arai H, Shibata N, Nishikawa R, Sugano I, Mikami K: [A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy]. Hinyokika Kiyo; 2010 Aug;56(8):447-51
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy].
  • No established treatment exists for urachal carcinoma,except curative resection,and its prognosis is poor.
  • We report a case of advanced urachal carcinoma treated with S-1 and cisplatin combination (S-1/CDDP) chemotherapy.
  • A tumor was detected on the bladder dome and transurethral resection was performed.
  • Histopathological findings indicated poorly differentiated adenocarcinoma.
  • The tumor was diagnosed as stage IVB (Sheldon's category) urachal carcinoma.
  • After one cycle of S-1/CDDP chemotherapy,the size of the tumor on the bladder dome decreased,after which total cystectomy was performed.
  • The surgical margin of the cystectomy specimen was negative for malignant cells,although poorly differentiated adenocarcinoma was still observed in this specimen.
  • The findings of this study indicate that this therapy might be beneficial for treating advanced urachal carcinomas.
  • This is the second report of successful treatment of advanced urachal carcinoma with S-1/CDDP chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus / abnormalities. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Drug Combinations. Female. Humans. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808064.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Kobayashi K, Furukawa A, Takahashi M, Murata K: Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response. Cardiovasc Intervent Radiol; 2003 May-Jun;26(3):234-41
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response.
  • PURPOSE: To evaluate the effects of neoadjuvant intra-arterial chemotherapy (NAIC) for locally advanced uterine cervical cancer, and to analyze factors influencing the response to the chemotherapy.
  • Six of the 14 stage III patients became operable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Infusions, Intra-Arterial. Neoadjuvant Therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adult. Aged. Antineoplastic Agents / administration & dosage. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / epidemiology. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Femoral Artery / radiography. Femoral Artery / surgery. Humans. Iliac Artery / radiography. Iliac Artery / surgery. Japan. Magnetic Resonance Imaging. Middle Aged. Necrosis. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome. Urinary Bladder / pathology. Women's Health


10. Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, Fragapane G: [Neuroendocrine small-cell bladder cancer: our experience]. Urologia; 2010 Oct-Dec;77 Suppl 17:64-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine small-cell bladder cancer: our experience].
  • [Transliterated title] Carcinoma neuroendocrino a piccole cellule della vescica; nostra esperienza.
  • INTRODUCTION: Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.35-0.70% of all bladder tumors.
  • Small-cell carcinoma is an epithelial tumor associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma.
  • At the time of presentation 59% of patients have clinical stage >T2 and 56% show metastatic disease.
  • PATIENTS AND METHODS: We report three cases of pure neuroendocrine small-cell bladder cancer.
  • Local advanced disease was present in all the cases with stage >T2, metastatic disease in 1 case, lymph node involvement and ureteral bilateral obstruction in 2.
  • Platinum-based adjuvant chemotherapy was proposed but only two patients received the treatment.
  • CONCLUSIONS: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain.
  • Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach will be the treatment of choice.
  • The association of chemotherapy and radiotherapy should also be considered.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hematuria / etiology. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Leukemia, Lymphocytic, Chronic, B-Cell. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasms, Second Primary. Peritoneal Neoplasms / secondary. Prostatic Neoplasms. Stomach Neoplasms. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308678.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Lee S, Ryoo H, Bae S, Song H, Kim M, Lee K, Lee W, Park K, Kim J, Baek J: Fixed dose rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced biliary cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed dose rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced biliary cancer.
  • : e15581 Background: Biliary cancer is diagnosed at advanced stage and recurrence is common after surgical resection.
  • Gemcitabine and UFT combination chemotherapy showed promising results in advanced pancreatic cancer(APC) and fixed dose- rate(FDR) infusion(10mg/m<sup>2</sup>/min) of gemcitabine is more effective than 30min-infusion in APC patients.
  • We conducted a prospective multicenter phase II study to evaluate the efficacy and toxicity of FDR gemcitabine and UFT combination chemotherapy in advanced biliary cancer(ABC) patients.
  • We evaluated the quality of life(QOL) and relationship between treatment outcome and polymorphisms of DNA repair gene such as RecQ1, RAD54L, XRCC1 and ATM.
  • METHODS: We included the chemo-naive patients with measurable metastatic or recurrent biliary adenocarcinoma except gall bladder cancer.
  • The estimated median time to progression(TTP) was 87 days(95% CI 51-123).
  • Grade 3/4 neutropenia was observed in 12 of 33 patients(36.4%) and 17 times of 114 cycles of chemotherapy(14.9%).
  • Polymorphism of XRCC1 was related to TTP(TTP of wild, heterozygous variant and homozygous variant type was 162, 71 and 25 days, respectively. p=0.0039).
  • QOL as a secondary endpoint was not analyzed at this time.
  • CONCLUSIONS: FDR infusion of gemcitabine and UFT combination chemotherapy in chemo-naïve patients with ABC is a well-tolerated and effective regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962362.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sharma A, Bedi R, Shukla NK, Raina V, Mohanti BK, Deo SV, Bedi NS, Garg P, Thulkar S, Rath GK: Does chemotherapy improve survival in gall bladder cancer? J Clin Oncol; 2004 Jul 15;22(14_suppl):4202

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemotherapy improve survival in gall bladder cancer?
  • : 4202 Background: Carcinoma of gall bladder is 4<sup>th</sup> commonest cancer in females in Northern India.
  • Majority of patients present in advanced inoperable stage where median survival is between 3-6 months and treatment options are analgesics, biliary stents, or palliative chemotherapy.
  • Oxaliplatin, has demonstrated some activity in advanced adenocarcinoma of gall bladder (Proc Am Soc Clin Oncol 2002:21; 142b).
  • To assess the impact of chemotherapy (5 FU, FA with or without Oxalipaltin) on survival this study was undertaken.
  • MATERIAL AND METHODS: 109 gall bladder cancer patients were seen from November 2000 to September 2003.
  • Pain was the commonest presenting symptom seen in 96 ( 88%) patients, 55 ( 51%) patients had gall bladder stones, and 80 ( 72%) patients had metastaic disease.
  • TREATMENT: 50 patients received only analgesics, simple cholecystectomy was done in 16, radical cholecystectomy in 15, and 13 patients received adjuvant radiotherapy without or with (9 patients) FUFA.
  • Oxaliplatin based palliative chemotherapy (FOLFOX or Oxaliplatin FUFA as reported earlier ASCO 2002:21; 142b or Oxaliplatin and Capecitabine) were used in 21 patients, and 5 patients received FUFA.
  • Any form of anti cancer treatment improved survival.
  • Median survival for patients who received no treatment versus palliative chemotherapy versus surgery followed by adjuvant treatment was 3, 5, and 10 months respectively ( p=0.0000).
  • Median survival for patients who received any form of chemotherapy versus no chemotherapy was 10 versus 4 months ( p=0.03).
  • CONCLUSIONS: This study reveals that patients receiving chemotherapy adjuvant or palliative had superior survival compared to others.
  • Oxaliplatin based chemotherapy FOLFOX in particular may be superior to others as palliative chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Koyama M, Inaba Y, Watabe S, Hayashi K, Ohe S, Kamio Y, Chiba M: [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. Gan To Kagaku Ryoho; 2002 Sep;29(9):1657-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
  • We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC).
  • Colonoscopy showed a type 3 advanced lower rectal cancer.
  • Examinations by computed tomography and chest X-ray revealed unresectable rectal cancer invading the sacrum and bladder with multiple liver and pulmonary metastases and swollen para-aortic lymph nodes.
  • After 10 courses of treatment with PMC, the primary lesion was remarkably reduced.
  • This chemotherapy also produced partial responses in the pulmonary metastases and para-aortic lymph node swelling.
  • The patient experienced few side effects and had good QOL in the terminal stage.
  • This chemotherapy regimen appears to be an effective and promising therapy with few side effects, even for patients with unresectable advanced colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Infusion Pumps, Implantable. Male. Middle Aged. Quality of Life. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12355956.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; U3P01618RT / Fluorouracil; 1-UFT protocol
  •  go-up   go-down


14. Hermida Pérez JA, Del Corral Suarez T, Cerdeiras Martínez G, Ochoa Undargarain O: [Hypernephroma associated with primary bladder tumor. Report of a case]. Arch Esp Urol; 2000 Mar;53(2):174-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypernephroma associated with primary bladder tumor. Report of a case].
  • [Transliterated title] Hipernefroma asociado a tumor primitivo vesical. Presentación de un caso.
  • OBJECTIVE: To present a case of tubular renal adenocarcinoma associated with transitional cell carcinoma of the bladder.
  • METHODS/RESULTS: A case of tubular renal adenocarcinoma associated with transitional cell carcinoma of the bladder in a 42-year-old patient is described.
  • Patient evaluation included intravenous urography, nephrotomograms, renal and bladder ultrasound evaluation and cystoscopic examination with biopsy.
  • The patient underwent nephroureterectomy and partial cystectomy with subsequent radiotherapy and intravesical chemotherapy.
  • CONCLUSIONS: The appearance of various early-stage urological tumors in the same patient, is uncommon.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10802926.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 14
  •  go-up   go-down


15. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • BACKGROUND: Palliative radiation therapy (RT) is an established tool in the management of symptoms caused by malignancies.
  • Most data on palliative RT is in regard to its use in the treatment of painful bone metastases.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • After undergoing 4 cycles of adjuvant chemotherapy, the patient did well for 5 months with no evidence of symptomatic, clinical, or radiographic recurrence of disease.
  • The patient was treated with another course of chemotherapy and pain was managed with relatively low doses of opioid medication (25mcg transdermal fentanyl patch, and oxycodone 5mg bid).
  • Ultimately a pain medication regimen of 200mcg transdermal fentanyl patch q2 days, oxycontin 20mg bid, oxycodone 5 - 10mg q 4 hours, ibuprofen 400mg q 8 hours, and gabapentin 600mg TID was not effective in controlling pain.
  • She was able to decrease pain medications, increase overall activity, and gain significant improvement in sleep quality and appetite even early on in the course of her radiation therapy.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pain / radiotherapy. Palliative Care / methods. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387350.001).
  • [ISSN] 1533-3159
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
  • PURPOSE: Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants.
  • MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5.
  • Pure neuroendocrine-type histology was identified in 16 cases, including 1 with small and large cell features, while the remaining 9 had mixed histology, that is transitional cell carcinoma in 8 and adenocarcinoma in 1.
  • Multi-agent chemotherapy was administered to 14 patients.
  • Patients receiving multimodality therapy had significantly better overall (p = 0.051) and recurrence-free (p = 0.003) survival than those treated with cystectomy alone.
  • CONCLUSIONS: Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis.
  • Adjuvant chemotherapy protocols may provide improved survival compared with cystectomy alone.
  • [MeSH-major] Cystectomy / methods. Neuroendocrine Tumors / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Khaled H, Emara ME, Gaafar RM, Mansour O, Abdel Warith A, Zaghloul MS, El Malt O: Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol Oncol; 2008 Mar-Apr;26(2):133-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial.
  • BACKGROUND: Gemcitabine is an active agent in the treatment of bladder cancer.
  • After an infusion during 30 minutes, this enzyme will be saturated, therefore, accumulation of higher intracellular concentrations of the active gemcitabine triphosphate could be achieved by prolonging the infusion time of gemcitabine.
  • PATIENTS AND METHODS: Based on previously published Phase I trials, the efficacy and safety of a combination of cisplatin and gemcitabine given as prolonged infusion were tried in a Phase II study of 57 untreated patients with stage III/IV bladder cancer, which is the most common malignant tumor among Egyptian males.
  • A total of 37 patients had transitional cell, 15 had squamous cell, 2 had adenocarcinoma, and 3 had undifferentiated cell carcinoma.
  • CONCLUSIONS: Prolonged infusion of gemcitabine and cisplatin is an effective treatment for advanced bilharzial-related bladder cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312930.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


19. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T, Radiation Therapy Oncology Group: Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys; 2004 May 1;59(1):168-73
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
  • A Phase II study was completed by the Radiation Therapy Oncology Group to assess the safety and toxicity of chemotherapy when combined with pelvic RT for these patients.
  • METHODS AND MATERIALS: Eligibility requirements included a total abdominal hysterectomy and bilateral salpingo-oophorectomy with Grade 2 or 3 endometrial adenocarcinoma with >50% myometrial invasion, stromal invasion of the cervix, or pelvic-confined extrauterine disease.
  • Vaginal brachytherapy with a low-dose-rate applicator (1 x 20 Gy to the surface) or high-dose-rate applicator (3 x 6 Gy to the surface) was performed after external beam RT.
  • Two patients were ineligible (one with previous bladder cancer and one who had undergone surgery >8 weeks before the start of RT).
  • The disease was Stage III, II, and I in 66%, 16%, and 18% of patients, respectively.
  • Two patients were not assessable because of incomplete treatment data.
  • Acute toxicity during RT/chemotherapy was Grade 1 in 27%, Grade 2 in 43%, Grade 3 in 27%, and Grade 4 in 2%.
  • During adjuvant chemotherapy, the toxicity was Grade 1 in 7%, Grade 2 in 7%, Grade 3 in 21%, and Grade 4 in 62%.
  • CONCLUSION: This treatment protocol demonstrated an excellent treatment completion rate and expected toxicity.
  • To assess the efficacy of this adjuvant treatment program, a Phase III trial (Radiation Therapy Oncology Group 9905) was designed with high-risk uterine-confined disease to be randomized between pelvic RT alone and pelvic RT with chemotherapy.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Paclitaxel / administration & dosage. Patient Compliance. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Survival Analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15093913.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Biewenga P, Mutsaerts MA, Stalpers LJ, Buist MR, Schilthuis MS, van der Velden J: Can we predict vesicovaginal or rectovaginal fistula formation in patients with stage IVA cervical cancer? Int J Gynecol Cancer; 2010 Apr;20(3):471-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can we predict vesicovaginal or rectovaginal fistula formation in patients with stage IVA cervical cancer?
  • INTRODUCTION: Patients with cervical carcinoma that invade the bladder or rectum (International Federation of Obstetrics and Gynecology stage IVA) have a high risk to develop vesicovaginal and/or rectovaginal fistulae.
  • If we could identify pretreatment factors that predict fistula formation, these patients could be offered less debilitating treatment.
  • MATERIALS AND METHODS: Data were retrieved from the database of consecutive patients diagnosed with stage IVA cervical cancer from 1992 to 2008.
  • RESULTS: Thirty patients with stage IVA cervical cancer were diagnosed.
  • Extension to the bladder was present in 27 patients; three patients had only rectal involvement.
  • Twenty-three patients (77%) had curative radiotherapy with or without chemotherapy and/or hyperthermia.
  • Seven patients (23%) received only palliative therapy or no treatment at all.
  • Five (22%) of these 23 patients developed one or more fistulae: 3 vesicovaginal, 1 rectovaginal, and 1 vesicovaginal and rectovaginal fistulae.
  • CONCLUSIONS: The risk to develop vesicovaginal and/or rectovaginal fistulae is high after curative radiotherapy with or without chemotherapy and/or hyperthermia in patients with stage IVA cervical cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Rectovaginal Fistula / diagnosis. Uterine Cervical Neoplasms / pathology. Vesicovaginal Fistula / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome. Urinary Bladder / pathology


21. Roohullah, Nusrat J, Hamdani SR, Burdy GM, Khurshid A: Cancer urinary bladder--5 year experience at Cenar, Quetta. J Ayub Med Coll Abbottabad; 2001 Apr-Jun;13(2):14-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer urinary bladder--5 year experience at Cenar, Quetta.
  • BACKGROUND: Purpose of this study was to see the incidence, age, sex, geographical distribution, symptoms, personal habits, signs, histo-pathology, early diagnosis and management of cases of Cancer Urinary Bladder (Ca UB) in the patients coming to CENAR, Quetta, Pakistan.
  • 97, in which about 100 cases of cancer of urinary bladder were included, out of which 82 patients were male and 12 were females.
  • Other histological types seen were squamous cell carcinoma (4%), Adenocarcinoma (3%), UD (5%) and HPNA (10%).
  • The patients were mainly treated with Radiotherapy, because at the time of reporting they were already in stage II or beyond (97%).
  • A few patients (6%) also received chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / epidemiology. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11732213.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


22. Jain G, Samaiya A, Mohindra N, Patel K: Bone metastases as the initial presentation of carcinoma of gall bladder: a rarity. Indian J Surg; 2009 Feb;71(1):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastases as the initial presentation of carcinoma of gall bladder: a rarity.
  • Distant metastases are rare form of presentation of carcinoma gall bladder.
  • Investigation showed metastatic adenocarcinoma in the head of humerus and the primary was found in the gall bladder.
  • She received local radiotherapy for bone metastases and undergoing systemic chemotherapy.
  • Carcinoma gall bladder is a common abdominal malignancy, mostly presenting in advanced stage with abdominal symptoms and obstructive jaundice.
  • In presence of metastasis, the management is palliative and role of chemotherapy is limited for palliation symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1981 Mar;68(3):161-5 [7470817.001]
  • [Cites] Indian J Cancer. 1994 Dec;31(4):257-9 [7875728.001]
  • [Cites] Indian J Gastroenterol. 1997 Apr;16(2):74 [9114585.001]
  • [Cites] Trop Gastroenterol. 1997 Jan-Mar;18(1):32-4 [9197173.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):1059 [10584859.001]
  • [Cites] Br J Radiol. 2002 Jan;75(889):72-3 [11806962.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Aug;18(8):950-3 [12859725.001]
  • [Cites] Ann Surg. 1962 Jul;156:114-24 [13891308.001]
  • [Cites] Cancer. 1949 May;2(3):379-98 [18131399.001]
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):930-1 [9755983.001]
  • [Cites] J Gastroenterol. 1997 Dec;32(6):852-6 [9430030.001]
  • (PMID = 23133106.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452562
  • [Keywords] NOTNLM ; Bone metastases / Carcinoma gall bladder / Chemotherapy
  •  go-up   go-down


23. Yamamoto S, Ito T, Akiyama A, Miki M, Tachibana M, Takase M, Matsumoto T, Mochizuki M: Primary signet-ring cell carcinoma of the urinary bladder inducing renal failure. Int J Urol; 2001 Apr;8(4):190-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell carcinoma of the urinary bladder inducing renal failure.
  • A case of primary signet-ring cell carcinoma of the urinary bladder that was found to have induced renal failure is the second such case reported in the world.
  • Primary signet-ring cell carcinoma of the urinary bladder is a rare histologic variant of adenocarcinoma.
  • The neoplasm had a high stage at diagnosis, so the prognosis was very poor.
  • To improve the prognosis, earlier diagnosis and establishing a regimen of chemotherapy is necessary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / complications. Renal Insufficiency / etiology. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11260353.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 12
  •  go-up   go-down


24. Marnitz S, Köhler C, Roth C, Füller J, Bischoff A, Wendt T, Schneider A, Budach V: Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol; 2007 Sep;183(9):473-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
  • PURPOSE: To evaluate the impact of transperitoneal laparoscopic staging on choice of subsequent therapy including oncologic outcome and toxicity of chemoradiation after surgical staging.
  • Only 17/101 patients (17%) retained their original FIGO stage after laparoscopy.
  • CONCLUSION: In patients with cervical cancer, laparoscopic staging led to an upstaging of 83% of cases with significant impact on therapeutic strategies.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Laparoscopy. Lymphatic Metastasis / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Rectum / pathology. Survival Rate. Urinary Bladder / pathology


25. Niu HT, Xu T, Zhang YB, Pang DQ, Zhang ZL, Wu S, Cheng B, Wang Y, Chang JW, Sun G: Outcomes for a large series of radical cystectomies for bladder cancer. Eur J Surg Oncol; 2008 Aug;34(8):911-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for a large series of radical cystectomies for bladder cancer.
  • AIMS: We present the characteristics and outcomes of a large Chinese series of patients treated with radical cystectomy and pelvic lymphadenectomy for invasive cancer of the bladder.
  • METHODS: The records of 356 patients with invasive bladder cancer, operated at three Chinese medical institutes between 1995 and 2004, were reviewed.
  • Of the 356 patients, 324 (91.0%) were TCC, 24 (6.7%) were adenocarcinoma, eight (2.3%) were squamous carcinoma.
  • In multivariate analysis, tumor configuration (RR=1.62, p=0.012), multiplicity (RR=1.41, p=0.036), histological subtype (RR=2.17, p<0.001), tumor stage (RR=2.50, p<0.001), tumor grade (RR=2.40, p<0.001), node status (RR=2.51, p<0.001), neoadjuvant chemotherapy (RR=0.46, p=0.016) had independent significance for survival on multivariate analysis.
  • CONCLUSIONS: The results of this series show that radical cystectomy and pelvic lymphadenectomy provide durable local control and DFS in patients with invasive bladder cancer.
  • Multivariates affect the prognosis after radical cystectomy for invasive bladder cancer.
  • The treatment of invasive bladder cancer in China is still in need of improvement and normalization.
  • [MeSH-major] Lymph Node Excision. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China. Cystectomy / methods. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Pelvis. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294806.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Hobdy EM, Ciesielski TE, Kummar S: Unusual sites of colorectal cancer metastasis. Clin Colorectal Cancer; 2003 May;3(1):54-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present 2 separate cases of adenocarcinoma of the colon with metastasis to the chin and the bladder, both of which are unusual sites of colorectal cancer metastasis.
  • Patient 1 is a 77-year-old man who was diagnosed with adenocarcinoma of the colon, American Joint Committee on Cancer (AJCC) T4 N0 M0 (stage II), and underwent a right hemicolectomy.
  • Fourteen months later he developed a firm 2.5-cm mass involving the chin.
  • Excisional biopsy revealed moderately differentiated adenocarcinoma, consistent with the known colon primary tumor.
  • Patient 2 is a 75-year-old man who was diagnosed with AJCC T3 N1 M0 (stage III) adenocarcinoma of the colon and underwent sigmoid colectomy.
  • Ten years later, he was found to have transitional cell carcinoma involving retroperitoneal nodes with no identifiable bladder or ureteral primary, for which he received chemotherapy.
  • Eighteen months following this diagnosis, he developed hematuria and was found to have metastatic colon adenocarcinoma involving the bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12777193.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic adenocarcinoma (PCa) (Gleason score 6) was diagnosed by needle biopsies.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.
  • After 1 course of chemotherapy, the patient was doing well.
  • Although the stage was advanced, the tumor was detected before urachal remnants were destroyed.
  • The treatment choice for urachal carcinomas is cystectomy.
  • Adjuvant chemotherapy and radiotherapy are controversial.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Morice P, Dargent D, Haie-Meder C, Duvillard P, Castaigne D: First case of a centropelvic recurrence after radical trachelectomy: literature review and implications for the preoperative selection of patients. Gynecol Oncol; 2004 Mar;92(3):1002-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To report the first case of a centropelvic recurrence in a patient who underwent a radical trachelectomy (RT) for a stage IB1 cervical carcinoma.
  • CASE: A 32-year-old woman presented with a stage IB1 adenocarcinoma that was treated by radical trachelectomy.
  • Twenty-six months after the surgical procedure, the patient became pregnant.
  • During the first trimester, ultrasonography depicted a suspicious lesion in the bladder.
  • Abdomino-pelvic magnetic resonance imaging (MRI) demonstrated a suspicious 20-mm tumor in the bladder associated with suspicious common iliac nodes.
  • The patient received external radiation therapy combined with concomitant chemotherapy.
  • A distance of 5 mm or less is likely to be too limited for radical trachelectomy to be accepted as treatment for cervical cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2004 Nov;95(2):414; author reply 414-6 [15491772.001]
  • (PMID = 14984977.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


29. Kotake M, Murakami N, Bandou H, Morita K, Koizumi H, Yoshino H, Tawaraya K, Ishiguro K, Kinoshita S, Yamada T: [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1955-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment].
  • Abdominal computed tomography (CT) revealed wall thickening of the small intestine and multiple lymph node metastases.
  • On the resected material a 5 x 4 cm type 2 tumor was identified.
  • Pathological findings included poorly-differentiated adenocarcinoma, si (bladder), n 4, P 0, ly 3, v 3, H 0, M(-), Stage IV.
  • The patient received the chemotherapy with TS-1.
  • TS-1(80 mg/body/day) orally administered for 4 weeks followed by a drug-free 2-week period as one course.
  • There were no drug side effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small. Lymph Nodes / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


30. Brooks S, Bownes P, Lowe G, Bryant L, Hoskin PJ: Cervical brachytherapy utilizing ring applicator: comparison of standard and conformal loading. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):934-9
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Afterloading high-dose-rate brachytherapy (HDR) treatment of cervical cancer with cross-sectional imaging and three-dimensional (3D) reconstruction offers opportunities for individualized conformal treatment planning rather than fixed point-A dosimetry.
  • METHODS AND MATERIALS: Between June 2003 and September 2004, 15 patients with FIGO Stage 1B-4A cervical carcinoma, median age 56 years, were treated with radical external-beam radiotherapy to pelvis, including paraortic nodes if positive on staging investigations.
  • Fourteen patients received concurrent cisplatin chemotherapy.
  • Clinical target volume (CTV) and organs at risk (OAR)--rectum, bladder, and small bowel--were outlined from postinsertion CT planning scans.
  • A standard plan was produced that delivered 6 Gy to point A, and a second plan delivered 6 Gy to PTV.
  • Constraints were defined for the OAR: bladder, 6 Gy; rectum, 5 Gy; and small bowel, 5 Gy.
  • RESULTS: Mean COIN values were 0.39 for conformal plans and 0.33 for standard plans (p = 0.001); mean D95 values were 4.79 Gy and 4.50 Gy, respectively.
  • CONCLUSION: The majority of patients achieved a plan closer to ideal for coverage of PTV, with minimization of radiation received by normal tissues for conformal loading measured by COIN compared with fixed point-A prescription that used the cervical ring applicator.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestine, Small / radiation effects. Middle Aged. Radiation Injuries / prevention & control. Rectum / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199322.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Neagoe A, Chira O, Acalovschi M, Dumitra D: Screening for familial colorectal cancer: the need for continuing education. A case report. Rom J Gastroenterol; 2003 Jun;12(2):139-41
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological diagnosis was moderate / poorly differentiated adenocarcinoma.
  • Resection of sigmoid colon was performed and adjuvant chemotherapy was carried out, with uneventful evolution.
  • The patient's mother, who was admitted at the same time, had been diagnosed with urinary bladder tumor.
  • It is important for such patients to be followed-up closely not only for recurrence or metastases, but also for detection and treatment of a second primary cancer at an early stage
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonoscopy. Colorectal Neoplasms / diagnosis. Sigmoid Neoplasms / diagnosis


32. Xiao Z, Tamimi Y, Brown K, Tulip J, Moore R: Interstitial photodynamic therapy in subcutaneously implanted urologic tumors in rats after intravenous administration of 5-aminolevulinic acid. Urol Oncol; 2002 May-Jun;7(3):125-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial photodynamic therapy in subcutaneously implanted urologic tumors in rats after intravenous administration of 5-aminolevulinic acid.
  • Photodynamic therapy (PDT) may be an attractive option for treatment of early stage prostate cancer.
  • We investigated the efficacy of ALA-mediated PDT for rat R3327-H prostate cancer, compared with the AY-27 bladder tumor.
  • At the day of PDT, animals were administered 500 mg/kg ALA intravenously 4 hours prior to laser therapy.
  • The mean time for R3327-H tumor to re-grow to 4 x treatment volume was 79.7 days in the control group (light only), 159 days in 1000 J group, and 169 days in 2000 J group (P < 0.05).
  • Likewise, for AY-27 tumors, the average time to re-grow to 4 x treatment volume was 13.7 days in the control group, 179.3, 183.3, and 185.7 days in groups of 1000, 1500, and 2000 J (P < 0.05), respectively.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Prostatic Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radionuclide imaging. Animals. Male. Rats. Rats, Inbred F344. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12474546.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


33. Velenik V, Oblak I, Anderluh F: Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol; 2010;5:88
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
  • METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the study.
  • Radiation dose was 45 Gy delivered as 25 fractions of 1.8 Gy.
  • Concurrent chemotherapy with oral capecitabine 825 mg/m² twice daily was administered during radiotherapy and at weekends.
  • Patients received four cycles of postoperative chemotherapy comprising either capecitabine 1250 mg/m² bid days 1-14 every 3 weeks or bolus i.v.
  • RESULTS: One patient died after receiving 27 Gy because of a pulmonary embolism.
  • Median follow-up time was 62 months.
  • The most frequent side-effect of the preoperative combined therapy was dermatitis (grade 3 in 19 patients).
  • The proportion of patients with severe late (SOMA grade 3 and 4) rectal, bladder and sexual toxicity was 40%, 19.2% and 51.7%, respectively.
  • CONCLUSIONS: This study confirms data from other non-randomised studies that capecitabine-based preoperative chemoradiation is a feasible treatment option for locally advanced rectal cancer, with positive 5-year overall survival, recurrence-free survival, and local control rates.
  • [MeSH-major] Adenocarcinoma / therapy. Neoadjuvant Therapy / methods. Rectal Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Capecitabine. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Digestive System Surgical Procedures. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Neoplasm Staging. Time

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2007 Aug;30(4):340-5 [17762432.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Mar;26(1):61-70 [17550133.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1333-7 [17987042.001]
  • [Cites] Int J Colorectal Dis. 2008 Feb;23(2):139-45 [17909820.001]
  • [Cites] Oncology. 2007;73(3-4):169-76 [18418009.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3983-91 [12351595.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Strahlenther Onkol. 2008 Sep;184(9):450-6 [19016023.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1190-7 [15026800.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1019-24 [15305186.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Radiother Oncol. 1995 Apr;35(1):17-60 [7569012.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5620-7 [16009958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):668-74 [16446339.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):361-71 [16500912.001]
  • [Cites] J Chemother. 2006 Feb;18(1):85-9 [16572898.001]
  • [Cites] Strahlenther Onkol. 2006 May;182(5):263-9 [16673059.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):318-24 [16703286.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] Strahlenther Onkol. 2006 Oct;182(10):596-603 [17013573.001]
  • [Cites] Croat Med J. 2006 Oct;47(5):693-700 [17042060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1378-83 [17056196.001]
  • [Cites] J Med Assoc Thai. 2006 Nov;89(11):1874-84 [17205868.001]
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):10-6 [17225940.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):378-84 [17097835.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1B):541-5 [17348439.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1389-93 [17394942.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1337-45 [10715306.001]
  • (PMID = 20920276.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2955594
  •  go-up   go-down


34. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report.
  • Most commonly metastatic skin incisional cancers have been reported with cancers of colon, kidney, and bladder.
  • It has been reported in few patients with adenocarcinoma and poorly differentiated histopathology, more so at drain site postoperatively.
  • We report a postoperative case of squamous cell carcinoma cervix FIGO stage IIA in a patient who after 3.5 years of completion of radical treatment (postoperative external and intravaginal radiation therapy) developed incisional skin metastasis followed by extensive subcutaneous metastasis in the vulval region.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.
  • The intent of treatment remains palliation either by radiation/chemotherapy/surgery alone or in combinations.
  • As far as we know, this is the first case of squamous cell carcinoma cervix stage IIA having incisional scar recurrence 3.5 years after postoperative radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Gynecologic Surgical Procedures. Humans. Radiotherapy


35. Kneist W, Heintz A, Wolf HK, Junginger T: [Total excision of the mesorectum in cancer of the lower and middle rectum. Oncological and functional results]. Chirurg; 2003 Feb;74(2):125-31
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Totale Mesorektumexzision bei Karzinom des mittleren und unteren Rektumdrittels. Onkologische und funktionelle Ergebnisse.
  • INTRODUCTION: The introduction of total mesorectal excision (TME) in the treatment of rectal cancer has improved survival rates and decreased recurrence.
  • Risk-factors for local recurrence should be identified since the indication for adjuvant therapy in "optimal surgery" has to be redefined.
  • PATIENTS AND METHODS: Between March 1997 and December 2001, 108 patients with adenocarcinoma of the lower and middle rectum were operated on by three surgeons according to the concept of total mesorectal excision.
  • There were 15 cases of stage IV (UICC) present and in 53 patients the tumor extension was restricted to the wall.
  • As surgical complications, anastomotic leakage occurred in 18% of cases, perineal wound infection in 33%, and bladder dysfunction (requiring catheterisation) in 5.6%.
  • CONCLUSIONS: TME offers good oncological and functional results with low complication rates for the treatment of cancer in the middle and upper third of the rectum.
  • Interdisciplinary multicenter studies are still necessary to redefine the place of adjuvant radiation and chemotherapy in cases of cancer in the lower two thirds of the rectum and stage III disease.
  • [MeSH-major] Adenocarcinoma / surgery. Postoperative Complications / etiology. Rectal Neoplasms / surgery. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12599030.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Le Bouëdec G, Bailly C, De Lapasse C, Gimbergues P, Dauplat J: [Retained ovarian remnant carcinoma: a case report]. J Gynecol Obstet Biol Reprod (Paris); 2006 Dec;35(8 Pt 1):829-33
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le cancer de l'ovaire rémanent: à propos d'une observation.
  • Ovarian remnant syndrome is defined as residual ovarian tissue non intentionally left in place by the surgeon during a bilateral salpingo-oophorectomy.
  • We report a case of adenocarcinoma arising in such an ovarian remnant revealed by vaginal bleeding 5 years after total abdominal hysterectomy and bilateral oophorectomy for uterine fibroids.
  • It was regarded as stage IIIc according to the FIGO classification because of common iliac lymph node involvement while there was no ascitis, no peritoneal nor omental implant but a unilateral hydronephrosis induced by extrinsec ureteral obstruction.
  • Complete cytoreductive surgery was achieved including partial bladder and lower ureteral resection with colpectomy, omentectomy, pelvic and para-aortic lymphadenectomy.
  • Paclitaxel-Platinum combination chemotherapy was given for nine cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / surgery. Hysterectomy / adverse effects. Ovarian Neoplasms / surgery. Ovariectomy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Salpingostomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151542.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 32
  •  go-up   go-down


37. Patel H, Joseph JV, Amodeo A, Kothari K: Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy? J Minim Access Surg; 2009 Oct;5(4):111-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for total pelvic exenteration in a male (removal of the bladder, prostate and rectum) and in a woman (removal bladder, uterus, vagina, ovaries and rectum) are rare.
  • The advanced stage generally dictates that the patient has some form of chemotherapy or radiotherapy, or a combination of two to shrink/debulk the tumour.
  • We report the first two cases of a salvage laparoscopic total pelvic exenteration in a male for rectal adenocarcinoma invading into the bladder and prostate, post-chemo-radiotherapy and in a woman for squamous cell carcinoma of cervix invading the bladder and rectum post-chemo-radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):907-18 [1115180.001]
  • [Cites] Surg Clin North Am. 1969 Apr;49(2):431-47 [4886910.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1023-30 [16890276.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Surg Oncol Clin N Am. 2005 Apr;14(2):289-300 [15817240.001]
  • [Cites] Semin Surg Oncol. 1999 Oct-Nov;17(3):161-7 [10504663.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):130-5 [8995561.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):207-10 [7896187.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):205-16 [3410348.001]
  • [Cites] Am J Obstet Gynecol. 1985 May 1;152(1):12-6 [2581447.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):934-43 [2586960.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):369-77 [14599868.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):311-5 [12217753.001]
  • [Cites] Semin Surg Oncol. 1999 Apr-May;16(3):236-41 [10225302.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):93-8 [2792911.001]
  • [Cites] Am J Obstet Gynecol. 1977 Dec 15;129(8):881-92 [930972.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):279-82 [2722049.001]
  • [Cites] Obstet Gynecol. 1989 Jun;73(6):1027-34 [2726106.001]
  • (PMID = 20407571.001).
  • [ISSN] 1998-3921
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2843126
  • [Keywords] NOTNLM ; Laparoscopy / malignancy / pelvic exenteration
  •  go-up   go-down


38. Heidrich DE: Delirium: an under-recognized problem. Clin J Oncol Nurs; 2007 Dec;11(6):805-7
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE STUDY: Ms. G, a 78-year-old woman with a history of heart failure and a left ventricular ejection fraction of 45%, had an exploratory laparotomy with colon resection and colostomy two days ago for an obstructive stage IIIB adenocarcinoma of the colon.
  • She has a patient-controlled analgesia (PCA) pump for postoperative pain control with 1 mg of morphine available every 30 minutes; she used a total of 4 mg of morphine via IV since midnight. Ms. G requires belladonna and opium suppositories about every eight hours to treat bladder spasms associated with her urinary catheter.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Belladonna Alkaloids / adverse effects. Causality. Colonic Neoplasms / surgery. Colostomy / adverse effects. Early Diagnosis. Female. Humans. Morphine / adverse effects. Nursing Assessment. Opium / adverse effects. Pain, Postoperative / drug therapy. Pain, Postoperative / etiology. Postoperative Care / methods. Postoperative Care / nursing. Urinary Catheterization / adverse effects

  • MedlinePlus Health Information. consumer health - Delirium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063538.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Belladonna Alkaloids; 76I7G6D29C / Morphine; 8008-60-4 / Opium
  •  go-up   go-down


39. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW: Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol; 2001 Jul;82(1):17-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
  • OBJECTIVE: Positive emission tomography (PET) provides a novel means of imaging malignancies.
  • The following study was undertaken to evaluate the predictive value of PET in determining a pathologic complete response in patients with advanced ovarian or peritoneal carcinoma who had a complete clinical response following primary chemotherapy.
  • METHODS: Twenty-two patients with advanced-stage ovarian (N = 17) or peritoneal (N = 5) carcinoma who had achieved complete clinical and radiologic remission and normal CA-125 level after six cycles of chemotherapy and who had consented to a second look laparotomy procedure were studied.
  • All patients received platinum based therapy and all but one patient, treated elsewhere, received paclitaxel in combination with platinum.
  • Various technical modifications including bladder activity dilution, intravenous hydration with diuretic therapy, and mechanical bowel preparations, were used to reduce background activity.
  • Intravenous hydration, diuretic therapy, and bowel preparation did not improve the results.
  • [MeSH-major] Adenocarcinoma, Mucinous / radionuclide imaging. Adenofibroma / radionuclide imaging. Carcinoma, Endometrioid / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging. Peritoneal Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / analysis. Female. Fluorodeoxyglucose F18. Humans. Laparotomy / methods. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging. Radiopharmaceuticals. Reoperation. Sensitivity and Specificity. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11426956.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. Kim CW, Kim JH, Yu CS, Shin US, Park JS, Jung KY, Kim TW, Yoon SN, Lim SB, Kim JC: Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):156-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The aim of the present study was to compare the influence of preoperative chemoradiotherapy (CRT) with postoperative CRT on the incidence and types of postoperative complications in rectal cancer patients who underwent sphincter-saving resection.
  • RESULTS: There was no between-group difference in age, gender, or cancer stage.
  • Delayed anastomotic leakage and rectovaginal fistulae developed more frequently in the pre-CRT group than in the post-CRT group (3.9% vs. 1.2%, p = 0.020, 6.5% vs. 1.3%, p = 0.027, respectively).
  • [MeSH-major] Adenocarcinoma. Anal Canal / surgery. Neoadjuvant Therapy / methods. Postoperative Complications / etiology. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Enteritis / etiology. Enteritis / surgery. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Ileostomy / statistics & numerical data. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Korea. Leucovorin / administration & dosage. Male. Middle Aged. Multivariate Analysis. Preoperative Care. Radiotherapy Dosage. Rectal Fistula / etiology. Rectal Fistula / surgery. Rectovaginal Fistula / etiology. Rectovaginal Fistula / therapy. Rectum / surgery. Urinary Bladder Fistula / etiology. Urinary Bladder Fistula / surgery. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20106604.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


41. Narayan K, van Dyk S, Bernshaw D, Rajasooriyar C, Kondalsamy-Chennakesavan S: Comparative study of LDR (Manchester system) and HDR image-guided conformal brachytherapy of cervical cancer: patterns of failure, late complications, and survival. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1529-35
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both groups matched for FIGO stage, MRI tumor volume, and uterine invasion status.
  • Sixty-eight percent (87/127) of patients treated by HDRc remained asymptomatic, whereas 42% (38/90) of patients were asymptomatic from the bowel and bladder symptoms after treatment with LDR.
  • The 5-year OS rate was 60% (SE = 4%).
  • The 5-year failure-free survival rate was 55% (SE = 3%).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / methods. Female. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Conformal / adverse effects. Radiotherapy, Conformal / methods. Radiotherapy, Conformal / mortality. Retrospective Studies. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473780.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • The predominant carcinomas were squamous cell (n = 21), transitional cell (TCC) (n = 15), and adenocarcinoma (n = 14).
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • Overall, there were no bladder recurrences.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Pathologic stage was predictive for local recurrence (P = 0.02) and CSS (P = 0.01).
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J: RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys; 2003 Nov 1;57(3):614-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
  • PURPOSE: This study determines the effect on toxicity of adding neoadjuvant hormonal therapy (NHT) to three-dimensional conformal radiation therapy (3D-CRT) in RTOG 94-06.
  • Two hundred and seven men initiated hormonal therapy (HT) between 2 to 3 months before 3D-CRT, and completed all HT no longer than 3 months after radiotherapy.
  • The 547 patients were treated at dose level I (68.4 Gy), level II (73.8 Gy), or level III (79.2 Gy).
  • Men were stratified into three risk groups according to their relative risk of seminal vesicle invasion: <15% (Group 1) vs. >15% (Group 2), or to T stage (T1, 2 vs. T3 tumors [Group 3]).
  • In Group 2 patients, there was a clinical target volume reduction to treat only the prostate after delivery of 55.8 Gy to a planning target volume including the seminal vesicles.
  • Hormonal therapy did not have a significant univariate effect on any other acute or late toxicity.
  • On multivariate analysis, the percent of the bladder (< or =30% vs. >30%) receiving > or = the reference dose (68.4 Gy, 73.8 Gy, or 79.2 Gy) (p = 0.0009, relative risk = 2.07, confidence interval: 1.88-2.28) was a significant predictor of acute GU effects.
  • However, this combined modality therapy significantly increased the risk of acute GU effects compared to 3D-CRT alone in men with poor baseline urinary function.
  • [MeSH-major] Hormones / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / adverse effects
  • [MeSH-minor] Adenocarcinoma. Aged. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Multivariate Analysis. Neoadjuvant Therapy. Prostate-Specific Antigen / blood. Radiation Injuries / prevention & control. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529764.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21661; United States / NCI NIH HHS / CA / CA60267; United States / NCI NIH HHS / CA / U10CA32115; United States / NCI NIH HHS / CA / U24 CA 81647
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


44. Callier C, Tauzin-Fin P, Bram R, Ballanger P: [Effect of sublingual oxybutynin in postoperative pain after radical retropubic prostatectomy]. Prog Urol; 2009 Sep;19(8):558-62
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Effet du traitement par l'oxybutynine en sublingual dans les douleurs postopératoires après prostatectomie totale.
  • INTRODUCTION: Total prostatectomy (TP) is one of the referential treatments of localized cancer of the prostate gland.
  • This study evaluates the efficiency of oxybutynin in the treatment of this postoperative pain (POP).
  • CONCLUSION: Oxybutynin given in sublingual form reduced, at postoperative stage, the frequency and intensity of pain linked to the bladder wound and to the catheter after TP.
  • Its use for the POP of the bladder section reduced the consumption of postoperative analgesia.
  • [MeSH-major] Mandelic Acids / therapeutic use. Muscarinic Antagonists / therapeutic use. Pain, Postoperative / drug therapy. Prostatectomy
  • [MeSH-minor] Adenocarcinoma / surgery. Administration, Sublingual. Aged. Humans. Male. Middle Aged. Pain Measurement. Prospective Studies. Prostatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699454.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Mandelic Acids; 0 / Muscarinic Antagonists; K9P6MC7092 / oxybutynin
  •  go-up   go-down


45. Chen Y, Xu H, Li Y, Wang D, Li J, Yuan J, Liang Z: The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol; 2008 Oct;15(10):2847-55
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean operation time was 162 min (range, 110-350), which included the learning curves of 3 surgeons.
  • Other medical problems included 47 cases (15.9%) of bladder dysfunction and 62 cases (21.0%) of rectum dysfunction or constipation.
  • CONCLUSION: Laparoscopic radical hysterectomy is a routine, effective treatment for patients with Ia2-IIb cervical carcinoma.
  • With more experience it is envisaged that IIb stage patients can be managed safely offering all the benefits of minimal surgery to the patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / pathology. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649105.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement